Lilly Asia Ventures has returned for genetic testing startup Veritas Genetics' series B round, where it was joined by Jiangsu Simcere Pharmaceutical.

Veritas Genetics, a US-based genetic testing technology producer spun out of Harvard University, has raised $30m in series B capital from investors including drug developer Jiangsu Simcere Pharmaceutical.

Lilly Asia Ventures, a corporate venturing subsidiary of pharmaceutical company Eli Lilly, also contributed to the round, which was led by growth equity firm Trustbridge Partners.

Founded in 2014, Veritas Genetics is developing a genome sequencing platform aimed at hereditary cancer and reproductive health, and has produced the first such product costing…